Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Nov 3:9:1039284.
doi: 10.3389/fmed.2022.1039284. eCollection 2022.

Fecal microbiota transplantation in irritable bowel syndrome: A meta-analysis of randomized controlled trials

Chatpol Samuthpongtorn  1 , Piyawat Kantagowit  1 , Rapat Pittayanon  2 , Tanisa Patcharatrakul  2   3 , Sutep Gonlachanvit  2   3
Affiliations

Fecal microbiota transplantation in irritable bowel syndrome: A meta-analysis of randomized controlled trials

Chatpol Samuthpongtorn et al. Front Med (Lausanne). .

Abstract

Introduction: Fecal microbiota transplantation (FMT) has been proposed as a potential treatment for irritable bowel syndrome (IBS); however, the consensus regarding its efficacy and safety is limited.

Materials and methods: We performed a systematic search of the literature using PubMed, EMBASE, Ovid MEDLINE, and Cochrane. Meta-analyses were conducted in relative risk (RR) or standard mean difference (SMD) using 95% confidence intervals (CI). Cochrane risk-of-bias 2 tool (RoB2) was employed to evaluate the study quality.

Result: Of 2,589 potential records, 7 studies with 9 cohorts involving 505 participants were included. Meta-analyses showed no significant difference in the short-term (12 weeks) and long-term (12 months) global improvement of IBS symptoms of FMT vs. placebo (RR 0.63, 95% CI 0.39-1.00 and RR 0.88, 95% CI 0.53-1.45, respectively). There were statistically significant differences of short-term IBS-SSS improvement (SMD -0.58, 95% CI -1.09 to -0.88) and short-term IBS-QoL improvement (SMD 0.67, 95% CI 0.43-0.91). Eight from 9 studies (88.9%) had a low risk of bias. The subgroup analysis revealed the short-term global symptoms improvement in studies with low-risk of bias (RR 0.53, 95% CI 0.35-0.81), studies with well-defined donors (RR 0.31, 95% CI 0.14-0.72), and studies with FMT using colonoscopy (RR 0.66, 95% CI 0.47-0.92). Major FMT adverse events are transient and rapidly self-limiting.

Conclusion: FMT significantly improved IBS-SSS and IBS-QoL in the short-term period in IBS patients. However, global symptom improvement showed no significance. Well-defined donors and appropriate fecal administration routes appear to be important factors for the successful outcomes of FMT in IBS.

Systematic review registration: [www.crd.york.ac.uk/prospero], identifier [CRD42021246101].

Keywords: dysbiosis; fecal microbiota transplantation; gastrointestinal diseases; irritable bowel syndrome; meta-analysis.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

FIGURE 1
FIGURE 1
PRISMA diagram.
FIGURE 2
FIGURE 2
Forest plot of global symptom of IBS between FMT and placebo. (A) Short term. (B) Long term.
FIGURE 3
FIGURE 3
Forest plot of IBS-SSS outcome between FMT and placebo. (A) Short term. (B) Long term.
FIGURE 4
FIGURE 4
Forest plot of IBS-QoL outcome between FMT and placebo. (A) Short term. (B) Long term.
See this image and copyright information in PMC

References

    1. Mearin F, Lacy B, Chang L, Chey W, Lembo A, Simren M, et al. Bowel disorders. Gastroenterology. (2016) 150:1393–407.e5. - PubMed
    1. Owyang C. Irritable bowel syndrome. 20th ed. In: Jameson J, Fauci AS, Kasper DL, Hauser SL, Longo DL, Loscalzo J. editors. Harrison’s principles of internal medicine. New York, NY: McGraw Hill; (2018).
    1. Sperber A, Dumitrascu D, Fukudo S, Gerson C, Ghoshal U, Gwee K, et al. The global prevalence of IBS in adults remains elusive due to the heterogeneity of studies: A Rome Foundation working team literature review. Gut. (2017) 66:1075–82. 10.1136/gutjnl-2015-311240 - DOI - PubMed
    1. Gralnek I, Hays R, Kilbourne A, Naliboff B, Mayer EA. The impact of irritable bowel syndrome on health-related quality of life. Gastroenterology. (2000) 119:654–60. 10.1053/gast.2000.16484 - DOI - PubMed
    1. Spiegel B. The burden of IBS: Looking at metrics. Curr Gastroenterol Rep. (2009) 11:265–9. 10.1007/s11894-009-0039-x - DOI - PubMed

Publication types

LinkOut - more resources